LEADER 03046nam 2200601 450 001 996466655403316 005 20220821200921.0 010 $a3-540-44662-1 024 7 $a10.1007/BFb0096328 035 $a(CKB)1000000000437210 035 $a(SSID)ssj0000324153 035 $a(PQKBManifestationID)12106224 035 $a(PQKBTitleCode)TC0000324153 035 $a(PQKBWorkID)10305290 035 $a(PQKB)10777437 035 $a(DE-He213)978-3-540-44662-0 035 $a(MiAaPQ)EBC5585780 035 $a(Au-PeEL)EBL5585780 035 $a(OCoLC)1066188290 035 $a(MiAaPQ)EBC6819077 035 $a(Au-PeEL)EBL6819077 035 $a(OCoLC)1159611150 035 $a(PPN)155198394 035 $a(EXLCZ)991000000000437210 100 $a20220821d1995 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt 182 $cc 183 $acr 200 13$aAn introduction to analysis on Wiener space /$fAli Su?leyman Ustu?nel 205 $a1st ed. 1995. 210 1$aBerlin :$cSpringer,$d[1995] 210 4$dİ1995 215 $a1 online resource (X, 102 p.) 225 1 $aLecture notes in mathematics (Springer-Verlag) ;$v1610 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-540-60170-8 320 $aIncludes bibliographical references and index. 327 $aPreliminaries -- Gross-Sobolev derivative, divergence and Ornstein-Uhlenbeck operator -- Meyer inequalities -- Hypercontractivity -- L p -multipliers theorem, meyer inequalities and distributions -- Some applications of the distributions -- Positive distributions and applications -- Characterization of independence of some Wiener functionals -- Moment inequalities for Wiener functional -- to the theorem of Ramer. 330 $aThis book gives the basis of the probabilistic functional analysis on Wiener space, developed during the last decade. The subject has progressed considerably in recent years thr- ough its links with QFT and the impact of Stochastic Calcu- lus of Variations of P. Malliavin. Although the latter deals essentially with the regularity of the laws of random varia- bles defined on the Wiener space, the book focuses on quite different subjects, i.e. independence, Ramer's theorem, etc. First year graduate level in functional analysis and theory of stochastic processes is required (stochastic integration with respect to Brownian motion, Ito formula etc). It can be taught as a 1-semester course as it is, or in 2 semesters adding preliminaries from the theory of stochastic processes It is a user-friendly introduction to Malliavin calculus! 410 0$aLecture notes in mathematics (Springer-Verlag) ;$v1610. 606 $aMalliavin calculus 615 0$aMalliavin calculus. 676 $a519.2 700 $aUstunel$b A. S$g(Ali Su?leyman),$061029 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a996466655403316 996 $aIntroduction to analysis on Wiener space$978089 997 $aUNISA LEADER 01235nam a2200301 i 4500 001 991003987549707536 008 081105s2008 de a b 001 0 eng d 020 $a9783540770152 035 $ab1378142x-39ule_inst 040 $aDip.to Matematica$beng 082 00$a514.74$222 084 $aLC QA564.P48 084 $aAMS 14C30 100 1 $aPeters, Chris$0149979 245 10$aMixed hodge structures /$cChris A. M. Peters, Joseph H. M. Steenbrink 260 $aBerlin :$bSpringer,$cc2008 300 $axiii, 470 p. :$bill. ;$c24 cm 490 1 $aErgebnisse der Mathematik und ihrer Grenzgebiete. 3. Folge,$x0071-1136 ;$v52 =$aA Series of modern surveys in mathematics ,$x0071-1136 ;$v52 504 $aIncludes bibliographical references (p. [445]-456) and indexes 650 0$aHodge theory 700 1 $aSteenbrink, J. H. M. 830 0$aErgebnisse der Mathematik und ihrer Grenzgebiete.$n3. Folge ;$v52 907 $a.b1378142x$b28-01-14$c05-11-08 912 $a991003987549707536 945 $aLE013 14C PET11 (2008)$g1$i2013000209517$lle013$op$pE129.95$q-$rl$s- $t0$u0$v0$w0$x0$y.i14894221$z02-12-08 996 $aMixed hodge structures$91224955 997 $aUNISALENTO 998 $ale013$b05-11-08$cm$da $e-$feng$gde $h0$i0 LEADER 04443nam 2200469z- 450 001 9910227346103321 005 20210211 035 $a(CKB)4100000000883872 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/42247 035 $a(oapen)doab42247 035 $a(EXLCZ)994100000000883872 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiomarkers in Drug Hypersensitivity 210 $cFrontiers Media SA$d2017 215 $a1 online resource (104 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-226-3 330 $aBiomarkers, especially those based on pharmacogenomics testing, have proved to be extremely useful for type A adverse drug reactions. Clinical practice guidelines based on biomarker testing are presently being developed and updated for type A adverse drug reactions. In contrast, little attention has been paid to the potential use of biomarkers in type B adverse reactions, characterized by the occurrence of reactions not directly related to the pharmacological properties of the drug. Drug-induced hypersensitivity belongs to those type B reactions. Drug-induced hypersensitivity reactions involve complex mechanisms that include, among others, the metabolic activation and haptenization of drug metabolites. Hence, factors that influence the pharmacokinetics of drug and metabolites may contribute to the development of some drug-induced hypersensitivity reactions. This implies that processes such as ADME (absorption, distribution, metabolism and excretion) that are typically involved in type A adverse drug reactions, may have a role in hypersensitivity reactions too. In addition to metabolic activation, several signal transduction pathways participate and modulate the development and the clinical presentation of drug hypersensitivity. The diverse mechanisms underlying such drug-hypersensitivity reactions lead to four major groups of reactions according to the Gell and Coombs classification: immediate, cytotoxic, immune complex and delayed. The enormous complexity of drug-hypersensitivity reactions is a consequence of the variety of mechanisms involved, which may be related, among others, to drug metabolism, generation of antigenic signals, stimulation and maturation of dendritic cells, presentation of haptens and mechanisms of cytotoxicity. In addition, a plethora of possible clinical presentations exists, including urticaria, angioedema, anaphylaxis, cytopenias, nephritis, serum sickness, vasculitis, contact dermatitis, drug rash, eosinophilia and systemic symptoms, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis. The rapid progress in the field in recent years indicates that the combination of several disciplines is essential to understand the mechanisms involved in this particular, and not completely understood, type of adverse drug reactions. The objective of this Research Topic is to present insights obtained from both basic and clinical scientists, which may include studies related to the identification, validation, refinement and clinical implementation of biomarkers for drug-induced hypersensitivity. The Topic aims to include recent findings related, but not limited to, potential phenomic, genomic, proteomic, metabolomic and signal transduction biomarkers. These biomarkers could eventually be used in clinical practice and/or these might contribute, as a proof of concept, to our understanding of the complex events leading to drug hypersensitivity reactions. In addition the Topic will cover recent developments and methodological advances in the diagnosis, prevention and therapeutic management of drug-induced hypersensitivity. 606 $aPharmacology$2bicssc 610 $abiomarkers 610 $adrug 610 $adrug metabolism 610 $agenotyping 610 $ahaptenization 610 $ahypersensitivity 610 $amodels 610 $aphenotyping 615 7$aPharmacology 700 $aEmanuela Corsini$4auth$01312093 702 $aSilvia Selinski$4auth 702 $aJose A. G. Agundez$4auth 702 $aElena Garcia-Martin$4auth 702 $aKlaus Golka$4auth 906 $aBOOK 912 $a9910227346103321 996 $aBiomarkers in Drug Hypersensitivity$93030677 997 $aUNINA